Samuel Banister

Company: Xylo Bio

Job title: Co-founder & Chief Scientific Officer

Seminars:

Development of Non-Hallucinogenic Neuroplastogens Targeting 5-HT2A for the Treatment of Psychiatric Disorders 8:50 am

Highlighting the profound therapeutic efficacy of psychedelics across numerous preclinical studies and clinical trials in psychiatry and neurology, and the commercialization involved in scaling access to psychedelic medicines. Describing the rational design and optimization of both hallucinogenic and nonhallucinogenic 5-HT2A agonists for clinical development. Discussing Xylo’s pipeline of novel neuroplastogens and the identification of development…Read more

day: Day Two